{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:01:16Z","timestamp":1794373276447,"version":"4.9.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41584-026-01427-w","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:13:04Z","timestamp":1788430384000},"page":"696-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccination considerations in autoimmune rheumatic diseases"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-514X","authenticated-orcid":false,"given":"Meliha C.","family":"Kapetanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1427_CR1","unstructured":"WHO. Immunization Agenda 2030: A Global Strategy to Leave No One Behind. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/strategy\/ia2030\/ia2030-draft-4-wha-b8850379-1fce-4847-bfd1-5d2c9d9e32f8.pdf (World Health Organization, 2020)."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"V Furer","year":"2019","unstructured":"Furer, V. et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5, e001041 (2019).","journal-title":"RMD Open"},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","volume":"11","author":"J Westra","year":"2015","unstructured":"Westra, J. et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 11, 135\u2013145 https:\/\/doi.org\/10.1038\/nrrheum.2014.206 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/annrheumdis-2021-221461","volume":"81","author":"H Bower","year":"2022","unstructured":"Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B. & Askling, J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Ann. Rheum. Dis. 81, 433\u2013439 https:\/\/doi.org\/10.1136\/annrheumdis-2021-221461 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/03007995.2025.2492646","volume":"41","author":"P Bhounsule","year":"2025","unstructured":"Bhounsule, P. et al. Influenza burden among chronic condition and immunocompromised patients in the United States. Curr. Med. Res. Opin. 41, 607\u2013615 https:\/\/doi.org\/10.1080\/03007995.2025.2492646 (2025).","journal-title":"Curr. Med. Res. Opin."},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"108840","DOI":"10.1016\/j.rmed.2026.108840","volume":"257","author":"YS Chang","year":"2026","unstructured":"Chang, Y. S. et al. Risk of influenza-related hospitalization and mortality in autoimmune inflammatory rheumatic diseases (AIIRD): insights on polymyositis\/dermatomyositis, Sj\u00f6gren\u2019s disease, and systemic sclerosis. Respir. Med. 257, 108840 (2026).","journal-title":"Respir. Med."},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s10067-020-05298-8","volume":"39","author":"RPV de Rezende","year":"2020","unstructured":"de Rezende, R. P. V., Klumb, E. M. & Pileggi, G. S. Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies. Clin. Rheumatol. 39, 2843\u20132844 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1427_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.vaccine.2022.11.075","volume":"41","author":"J Nagel","year":"2023","unstructured":"Nagel, J. et al. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. Vaccine 41, 504\u2013510 (2023).","journal-title":"Vaccine"},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3899\/jrheum.160909","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"Mohammad, A. J. et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J. Rheumatol. 44, 1468\u20131475 (2017).","journal-title":"J. Rheumatol."},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/rheumatology\/keaa699","volume":"60","author":"J Rathmann","year":"2021","unstructured":"Rathmann, J., Jayne, D., Segelmark, M., J\u00f6nsson, G. & Mohammad, A. J. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology 60, 2745\u20132754 (2021).","journal-title":"Rheumatology"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera, P. A., Lasa, J. S., Bonovas, S., Danese, S. & Peyrin-Biroulet, L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158, 1554\u20131573.e12 (2020).","journal-title":"Gastroenterology"},{"key":"1427_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152099","volume":"57","author":"T Ko","year":"2022","unstructured":"Ko, T. et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin. Arthritis Rheum. 57, 152099 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"1427_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2026.152969","volume":"78","author":"SH You","year":"2026","unstructured":"You, S. H. et al. Multimorbidity and risk of infection in patients with rheumatoid arthritis: Population-based case-control study. Semin. Arthritis Rheum. 78, 152969 https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152969 (2026).","journal-title":"Semin. Arthritis Rheum."},{"key":"1427_CR14","first-page":"296","volume":"45","author":"A Lo Presti","year":"2022","unstructured":"Lo Presti, A. et al. Hepatitis B and C virus infection in patients with systemic and cutaneous lupus erythematosus. New Microbiol. 45, 296\u2013303 (2022).","journal-title":"New Microbiol."},{"key":"1427_CR15","volume":"44","author":"M Li","year":"2025","unstructured":"Li, M. et al. Reduced HBsAg positivity in systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome: a retrospective comparative study. Biochem. Biophys. Rep. 44, 102275 (2025).","journal-title":"Biochem. Biophys. Rep."},{"key":"1427_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152846","volume":"75","author":"JP Enns","year":"2025","unstructured":"Enns, J. P. et al. Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease. Semin. Arthritis Rheum. 75, 152846 https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152846 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-025-02371-z","volume":"10","author":"Y Fu","year":"2025","unstructured":"Fu, Y. et al. Immunosenescence: signaling pathways, diseases and therapeutic targets. Signal. Transduct. Target. Ther. 10, 250 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1427_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/vaccines13111130","volume":"13","author":"CA Hitchon","year":"2025","unstructured":"Hitchon, C. A. et al. COVID-19 vaccination, hospitalization rates, and mortality differ between people with diagnosed immune mediated inflammatory disease and the general population: a population-based study. Vaccines 13, 1130 https:\/\/doi.org\/10.3390\/vaccines13111130 (2025).","journal-title":"Vaccines"},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","volume":"362","author":"DC Wraith","year":"2003","unstructured":"Wraith, D. C., Goldman, M. & Lambert, P. H. Vaccination and autoimmune disease: what is the evidence? Lancet 362, 1659\u20131666 (2003).","journal-title":"Lancet"},{"key":"1427_CR20","doi-asserted-by":"publisher","unstructured":"Giri, P. S., Shoenfeld, Y., Dwivedi, M. K. in Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases 1st edn, Vol. 2 (eds Dwivedi, M. K. et al.) 19\u201355 https:\/\/doi.org\/10.1007\/978-981-19-4800-8_2 (Springer, 2022).","DOI":"10.1007\/978-981-19-4800-8_2"},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12016-025-09124-4","volume":"68","author":"CC Tzang","year":"2025","unstructured":"Tzang, C. C. et al. Association between COVID-19 and new-onset autoimmune diseases: updated systematic review and meta-analysis of 97 million individuals. Clin. Rev. Allergy Immunol. 68, 111 https:\/\/doi.org\/10.1007\/s12016-025-09124-4 (2025).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","volume":"9","author":"F Klok","year":"2021","unstructured":"Klok, F. et al. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 9, e73\u2013e80 (2021).","journal-title":"Lancet Haematol."},{"key":"1427_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01279-7","author":"J Rayes","year":"2026","unstructured":"Rayes, J. & Bayry, J. Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis. Nat. Rev. Cardiol. https:\/\/doi.org\/10.1038\/s41569-026-01279-7 (2026).","journal-title":"Nat. Rev. Cardiol."},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12012-026-10123-w","volume":"26","author":"A Ardizzone","year":"2026","unstructured":"Ardizzone, A. et al. Assessing the risk of myocarditis post-COVID-19 vaccination: a systematic review of case reports from 2023 to 2025. Cardiovasc. Toxicol. 26, 47 https:\/\/doi.org\/10.1007\/s12012-026-10123-w (2026).","journal-title":"Cardiovasc. Toxicol."},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger, L. B. et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977. Am. J. Epidemiol. 110, 105\u2013123 https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a112795 (1979).","journal-title":"Am. J. Epidemiol."},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"d3908","DOI":"10.1136\/bmj.d3908","volume":"343","author":"J Dieleman","year":"2011","unstructured":"Dieleman, J. et al. VAESCO-GBS Case\u2013Control Study Group. Guillain\u2013Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. Br. Med. J. 343, d3908 https:\/\/doi.org\/10.1136\/bmj.d3908 (2011).","journal-title":"Br. Med. J."},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","volume":"181","author":"R Goud","year":"2021","unstructured":"Goud, R. et al. Risk of Guillain\u2013Barr\u00e9 syndrome following recombinant zoster vaccine in Medicare beneficiaries. JAMA Intern. Med. 181, 1623\u20131630 (2021).","journal-title":"JAMA Intern. Med."},{"key":"1427_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152911","volume":"77","author":"J Ciaffi","year":"2026","unstructured":"Ciaffi, J., Torrigiani, G., Ruscitti, P., Zambon, A. & Ursini, F. COVID-19 vaccination and systemic autoimmune rheumatic diseases: no evidence of disproportionately increased reporting in VAERS. Semin. Arthritis Rheum. 77, 152911 https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152911 (2026).","journal-title":"Semin. Arthritis Rheum."},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","volume":"403","author":"A Shattock","year":"2024","unstructured":"Shattock, A. et al. Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization. Lancet 403, 2307\u20132316 (2024).","journal-title":"Lancet"},{"key":"1427_CR30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/keac484","volume":"62","author":"G Nakafero","year":"2023","unstructured":"Nakafero, G. et al. Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis. Rheumatology 62, 1445\u20131450 https:\/\/doi.org\/10.1093\/rheumatology\/keac484 (2023).","journal-title":"Rheumatology"},{"key":"1427_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.919979","volume":"13","author":"Y Xie","year":"2022","unstructured":"Xie, Y., Liu, Y. & Liu, Y. The flare of rheumatic disease after SARS-CoV-2 vaccination: a review. Front. Immunol. 13, 919979 https:\/\/doi.org\/10.3389\/fimmu.2022.919979 (2022).","journal-title":"Front. Immunol."},{"key":"1427_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102243","volume":"65","author":"JJ Paik","year":"2022","unstructured":"Paik, J. J., Sparks, J. A. & Kim, A. H. J. Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Curr. Opin. Pharmacol. 65, 102243 https:\/\/doi.org\/10.1016\/j.coph.2022.102243 (2022).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1427_CR33","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00296-024-05734-x","volume":"44","author":"P Dhanasekaran","year":"2024","unstructured":"Dhanasekaran, P., Karasu, B. T. & Mak, A. Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review. Rheumatol. Int. 44, 2757\u20132794 https:\/\/doi.org\/10.1007\/s00296-024-05734-x (2024).","journal-title":"Rheumatol. Int."},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/rheumatology\/keac604","volume":"62","author":"SYS Tan","year":"2023","unstructured":"Tan, S. Y. S., Yee, A. M., Sim, J. J. L. & Lim, C. C. COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance. Rheumatology 62, 1757\u20131772 https:\/\/doi.org\/10.1093\/rheumatology\/keac604 (2023).","journal-title":"Rheumatology"},{"key":"1427_CR35","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1136\/annrheumdis-2019-215086","volume":"78","author":"G Nakafero","year":"2019","unstructured":"Nakafero, G. et al. Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink. Ann. Rheum. Dis. 78, 1122\u20131126 https:\/\/doi.org\/10.1136\/annrheumdis-2019-215086 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1427_CR36","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/rheumatology\/keae160","volume":"64","author":"G Nakafero","year":"2025","unstructured":"Nakafero, G. et al. Uptake and safety of pneumococcal vaccination in adults with immune-mediated inflammatory diseases: a UK wide observational study. Rheumatology 64, 962\u2013968 https:\/\/doi.org\/10.1093\/rheumatology\/keae160 (2025).","journal-title":"Rheumatology"},{"key":"1427_CR37","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1016\/S2665-9913(25)00313-3","volume":"8","author":"N Aikawa","year":"2026","unstructured":"Aikawa, N. et al. Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study. Lancet Rheumatol. 8, e363\u2013e376 (2026).","journal-title":"Lancet Rheumatol."},{"key":"1427_CR38","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S2665-9913(24)00084-5","volume":"6","author":"JK Park","year":"2024","unstructured":"Park, J. K. et al. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 6, e352\u2013e360 https:\/\/doi.org\/10.1016\/S2665-9913(24)00084-5 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ard.2026.01.002","volume":"85","author":"JA Hawkins","year":"2026","unstructured":"Hawkins, J. A. et al. Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial. Ann. Rheum. Dis. 85, 787\u2013796 https:\/\/doi.org\/10.1016\/j.ard.2026.01.002 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"1427_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2263979","volume":"19","author":"R Parikh","year":"2023","unstructured":"Parikh, R., Singer, D., Chmielewski-Yee, E. & Dessart, C. Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence. Hum. Vaccin. Immunother. 19, 2263979 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1427_CR41","doi-asserted-by":"publisher","unstructured":"Mok, C. C. Herpes zoster vaccination and flares in rheumatic diseases. Lancet Rheumatol. https:\/\/doi.org\/10.1016\/S2665-9913(25)00340-6 (2026).","DOI":"10.1016\/S2665-9913(25)00340-6"},{"key":"1427_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 https:\/\/doi.org\/10.1038\/s41577-020-00479-7 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1427_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass, A. R. et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res. 75, 449\u2013464 https:\/\/doi.org\/10.1002\/acr.25045 (2023).","journal-title":"Arthritis Care Res."},{"key":"1427_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer, V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 39\u201352 https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1427_CR45","unstructured":"EULAR. EULAR QoC ongoing initiatives: QoC024 - 2024 update on vaccination recommendations for patients with autoimmune inflammatory rheumatic diseases. EULAR https:\/\/www.eular.org\/ongoing-initiatives (2026)."},{"key":"1427_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41584-023-00992-8","volume":"19","author":"Y van Sleen","year":"2023","unstructured":"van Sleen, Y., van der Geest, K. S. M., Huckriede, A. L. W., van Baarle, D. & Brouwer, E. Effect of DMARDs on the immunogenicity of vaccines. Nat. Rev. Rheumatol. 19, 560\u2013575 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1427_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128399","volume":"78","author":"X Wang","year":"2026","unstructured":"Wang, X. et al. Immunisation against vaccine-preventable diseases in individuals receiving immunosuppressive targeted therapies. Vaccine 78, 128399 https:\/\/doi.org\/10.1016\/j.vaccine.2026.128399 (2026).","journal-title":"Vaccine"},{"key":"1427_CR48","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1016\/S2665-9913(25)00071-2","volume":"7","author":"J Morel","year":"2025","unstructured":"Morel, J. et al. I-REIVAC; CRI-IMIDIATE French Clinical Research Networks. Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial. Lancet Rheumatol. 7, e675\u2013e686 https:\/\/doi.org\/10.1016\/S2665-9913(25)00071-2 (2025).","journal-title":"Lancet Rheumatol."},{"key":"1427_CR49","unstructured":"Abhishek, A. et al. Temporary 2-Week Suspension of Methotrexate Treatment to Enhance COVID-19 Vaccine Response in People with Immune-mediated Inflammatory Diseases: The Vroom RCT (National Institute for Health and Care Research, 2025)."},{"key":"1427_CR50","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/annrheumdis-2021-220435","volume":"80","author":"T Graalmann","year":"2021","unstructured":"Graalmann, T. et al. B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner. Ann. Rheum. Dis. 80, 1537\u20131544 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1427_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-024-03297-7","volume":"26","author":"S Pollastro","year":"2024","unstructured":"Pollastro, S. et al. ABIRISK Consortium. Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis. Arthritis Res. Ther. 26, 70 https:\/\/doi.org\/10.1186\/s13075-024-03297-7 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"1427_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1747777","volume":"17","author":"J Li","year":"2026","unstructured":"Li, J., Guo, Q., Li, L., Wang, J. & Zhang, L. CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. Front. Immunol. 17, 1747777 https:\/\/doi.org\/10.3389\/fimmu.2026.1747777 (2026).","journal-title":"Front. Immunol."},{"key":"1427_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","volume":"63","author":"X Lyu","year":"2024","unstructured":"Lyu, X., Gupta, L., Tholouli, E. & Chinoy, H. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. Rheumatology 63, 1206\u20131216 https:\/\/doi.org\/10.1093\/rheumatology\/kead616 (2024).","journal-title":"Rheumatology"},{"key":"1427_CR54","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 https:\/\/doi.org\/10.1038\/s41584-024-01139-z (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1427_CR55","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41591-026-04430-6","volume":"32","author":"G Schett","year":"2026","unstructured":"Schett, G. & Xu, H. Resetting autoimmune disease with CAR cell therapies. Nat. Med. 32, 2007\u20132016 https:\/\/doi.org\/10.1038\/s41591-026-04430-6 (2026).","journal-title":"Nat. Med."},{"key":"1427_CR56","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat, J. & Barmettler, S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J. Allergy Clin. Immunol. Pract. 10, 460\u2013466 https:\/\/doi.org\/10.1016\/j.jaip.2021.10.037 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"1427_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71473-1","author":"S Ozog","year":"2026","unstructured":"Ozog, S. et al. Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-71473-1 (2026).","journal-title":"Nat. Commun."},{"key":"1427_CR58","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","volume":"32","author":"F M\u00fcller","year":"2026","unstructured":"M\u00fcller, F. et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat. Med. 32, 1142\u20131151 https:\/\/doi.org\/10.1038\/s41591-025-04185-6 (2026).","journal-title":"Nat. Med."},{"key":"1427_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14109","volume":"25","author":"G Reynolds","year":"2023","unstructured":"Reynolds, G., Hall, V. G. & Teh, B. W. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl. Infect. Dis. 25, e14109 https:\/\/doi.org\/10.1111\/tid.14109 (2023).","journal-title":"Transpl. Infect. Dis."},{"key":"1427_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476","volume":"69","author":"R Greco","year":"2024","unstructured":"Greco, R. et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine 69, 102476 https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476 (2024).","journal-title":"EClinicalMedicine"},{"key":"1427_CR61","doi-asserted-by":"publisher","first-page":"e0010002","DOI":"10.1371\/journal.pntd.0010002","volume":"15","author":"AC Tonacio","year":"2021","unstructured":"Tonacio, A. C. et al. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. PLoS Negl. Trop. Dis. 15, e0010002 https:\/\/doi.org\/10.1371\/journal.pntd.0010002 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1427_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2021.100131","volume":"10","author":"N Emi Aikawa","year":"2021","unstructured":"Emi Aikawa, N. et al. Yellow fever vaccination in Brazil: short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases. Vaccine X 10, 100131 https:\/\/doi.org\/10.1016\/j.jvacx.2021.100131 (2021).","journal-title":"Vaccine X"},{"key":"1427_CR63","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10067-021-05962-7","volume":"41","author":"BS Dos Reis","year":"2022","unstructured":"Dos Reis, B. S. et al. Seroconversion of rheumatoid arthritis patients after yellow fever vaccination. Clin. Rheumatol. 41, 705\u2013708 https:\/\/doi.org\/10.1007\/s10067-021-05962-7 (2022).","journal-title":"Clin. Rheumatol."},{"key":"1427_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa126","volume":"27","author":"S B\u00fchler","year":"2020","unstructured":"B\u00fchler, S. et al. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1. J. Travel Med. 27, taaa126 https:\/\/doi.org\/10.1093\/jtm\/taaa126 (2020).","journal-title":"J. Travel Med."},{"key":"1427_CR65","doi-asserted-by":"publisher","unstructured":"Majri, A. L. & Chan, J. Safety of live and live-attenuated vaccines in patients receiving biologics and small-molecule therapies for dermatologic diseases: a systematic review. Australas. J. Dermatol. https:\/\/doi.org\/10.1111\/ajd.70088 (2026).","DOI":"10.1111\/ajd.70088"},{"key":"1427_CR66","unstructured":"WHO. MVA-BN (Modified Vaccinia Ankara \u2013 Bavarian Nordic) Smallpox and Mpox Vaccine: Interim Guidance, 27 November 2024. https:\/\/www.who.int\/publications\/i\/item\/B09202 (World health Organization, 2024)."},{"key":"1427_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-391","volume":"14","author":"AC Campi-Azevedo","year":"2014","unstructured":"Campi-Azevedo, A. C. et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis. 14, 391 https:\/\/doi.org\/10.1186\/1471-2334-14-391 (2014).","journal-title":"BMC Infect. Dis."},{"key":"1427_CR68","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/infdis\/jix314","volume":"216","author":"J Toresi","year":"2017","unstructured":"Toresi, J. et al. Replication and excretion of the live attenuated tetravalent Dengue vaccine CYD-TDV in a flavivirus-naive adult population: assessment of vaccine viremia and virus shedding. J. Infect. Dis. 216, 834\u2013841 https:\/\/doi.org\/10.1093\/infdis\/jix314 (2017).","journal-title":"J. Infect. Dis."},{"key":"1427_CR69","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1016\/j.vaccine.2022.06.013","volume":"40","author":"J Mischlinger","year":"2022","unstructured":"Mischlinger, J. et al. Long-term persistence of antibodies after diphtheria\/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls. Vaccine 40, 4897\u20134904 https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.013 (2022).","journal-title":"Vaccine"},{"key":"1427_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/ar4427","volume":"16","author":"MC Kapetanovic","year":"2014","unstructured":"Kapetanovic, M. C. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res. Ther. 16, R2 https:\/\/doi.org\/10.1186\/ar4427 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1427_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/ar4127","volume":"15","author":"M Crnkic Kapetanovic","year":"2013","unstructured":"Crnkic Kapetanovic, M., Saxne, T., Truedsson, L. & Geborek, P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res. Ther. 15, R1 https:\/\/doi.org\/10.1186\/ar4127 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1427_CR72","doi-asserted-by":"publisher","first-page":"e002008","DOI":"10.1136\/rmdopen-2021-002008","volume":"7","author":"UM Geisen","year":"2021","unstructured":"Geisen, U. M. et al. Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies. RMD Open 7, e002008 https:\/\/doi.org\/10.1136\/rmdopen-2021-002008 (2021).","journal-title":"RMD Open"},{"key":"1427_CR73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-025-03553-4","volume":"27","author":"J Marin","year":"2025","unstructured":"Marin, J. et al. The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab. Arthritis Res. Ther. 27, 86 https:\/\/doi.org\/10.1186\/s13075-025-03553-4 (2025).","journal-title":"Arthritis Res. Ther."},{"key":"1427_CR74","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.191266","volume":"11","author":"M Mackay","year":"2025","unstructured":"Mackay, M. et al. Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial. JCI Insight 11, e191266 https:\/\/doi.org\/10.1172\/jci.insight.191266 (2025).","journal-title":"JCI Insight"},{"key":"1427_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova, A. et al. Zoster-049 Study Group. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect. Dis. 9, ofac485 https:\/\/doi.org\/10.1093\/ofid\/ofac485 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"1427_CR76","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1093\/rheumatology\/keaa078","volume":"59","author":"G Nakafero","year":"2020","unstructured":"Nakafero, G. et al. Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs. Rheumatology 59, 3666\u20133675 https:\/\/doi.org\/10.1093\/rheumatology\/keaa078 (2020).","journal-title":"Rheumatology"},{"key":"1427_CR77","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1016\/S2665-9913(24)00128-0","volume":"6","author":"G Nakafero","year":"2024","unstructured":"Nakafero, G. et al. Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case\u2013control study. Lancet Rheumatol. 6, e615\u2013e624 https:\/\/doi.org\/10.1016\/S2665-9913(24)00128-0 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1427_CR78","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2665-9913(23)00272-2","volume":"6","author":"JS Hanberg","year":"2024","unstructured":"Hanberg, J. S. et al. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. Lancet Rheumatol. 6, e21\u2013e30 https:\/\/doi.org\/10.1016\/S2665-9913(23)00272-2 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1427_CR79","doi-asserted-by":"publisher","first-page":"e005839","DOI":"10.1136\/rmdopen-2025-005839","volume":"11","author":"SE Mayer","year":"2025","unstructured":"Mayer, S. E. et al. Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA. RMD Open 11, e005839 https:\/\/doi.org\/10.1136\/rmdopen-2025-005839 (2025).","journal-title":"RMD Open"},{"key":"1427_CR80","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/vaccines13121227","volume":"13","author":"S Valentini","year":"2025","unstructured":"Valentini, S. et al. Effectiveness and safety of recombinant zoster vaccine in rheumatic diseases: real-world evidence from a single-centre Italian cohort. Vaccines 13, 1227 (2025).","journal-title":"Vaccines"},{"key":"1427_CR81","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ard.2025.01.045","volume":"84","author":"E Rayens","year":"2025","unstructured":"Rayens, E. et al. Effectiveness and safety of the recombinant zoster vaccine in individuals \u226550 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Ann. Rheumatic Dis. 84, 960\u2013969 (2025).","journal-title":"Ann. Rheumatic Dis."},{"key":"1427_CR82","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6154-25","author":"Y Tabata","year":"2025","unstructured":"Tabata, Y. et al. Preventive effectiveness of recombinant zoster vaccine in rheumatoid arthritis patients treated with janus kinase inhibitors. Intern. Med. https:\/\/doi.org\/10.2169\/internalmedicine.6154-25 (2025).","journal-title":"Intern. Med."},{"key":"1427_CR83","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/rheumatology\/kex523","volume":"57","author":"SC Kim","year":"2018","unstructured":"Kim, S. C., Feldman, S. & Moscicki, A. B. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology 57, v26\u2013v33 (2018).","journal-title":"Rheumatology"},{"key":"1427_CR84","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1016\/j.vaccine.2007.08.024","volume":"25","author":"FX Heinz","year":"2007","unstructured":"Heinz, F. X., Holzmann, H., Essl, A. & Kundi, M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25, 7559\u20137567 https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.024 (2007).","journal-title":"Vaccine"},{"key":"1427_CR85","unstructured":"Buchholz, K. COVID-19 pandemic. The countries where COVID-19 vaccination is mandatory. Statista https:\/\/www.statista.com\/chart\/25326\/obligatory-vaccination-against-covid-19\/?srsltid=AfmBOoqo71m19RtibLylZ1oc7Wn0jf_NFAJB_8sWQ5T8bHiuLYErtlC9 (2026)."},{"key":"1427_CR86","doi-asserted-by":"crossref","unstructured":"Halsey E. S. et al. CDC Yellow Book, 2026 Edition: Health Information for International Travel (Centers for Disease Control and Prevention, 2025).","DOI":"10.1093\/oso\/9780197788547.001.0001"},{"key":"1427_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2024.102784","volume":"63","author":"AA Khan","year":"2025","unstructured":"Khan, A. A. et al. Vaccinations for Hajj: enhancing health and global health security. Travel Med. Infect. Dis. 63, 102784 https:\/\/doi.org\/10.1016\/j.tmaid.2024.102784 (2025).","journal-title":"Travel Med. Infect. Dis."},{"key":"1427_CR88","unstructured":"WHO. Measles. World Health Organization https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/measles (2026)."},{"key":"1427_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.JAA.0000000000000328","volume":"39","author":"L Solano","year":"2026","unstructured":"Solano, L. & Smith, R. Addressing the crises of declining vaccination rates and measles resurgence by promoting health literacy. JAAPA 39, 16\u201322 https:\/\/doi.org\/10.1097\/01.JAA.0000000000000328 (2026).","journal-title":"JAAPA"},{"key":"1427_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keag123","volume":"65","author":"S Mehouachi","year":"2026","unstructured":"Mehouachi, S., Mongin, D., Eperon, G., Courvoisier, D. S. & Lauper, K. Vaccination rates in rheumatic diseases: a cross-sectional register study on the role of patient beliefs and physician engagement. Rheumatology 65, keag123 https:\/\/doi.org\/10.1093\/rheumatology\/keag123 (2026).","journal-title":"Rheumatology"},{"key":"1427_CR91","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41927-025-00608-6","volume":"10","author":"A Suslow","year":"2026","unstructured":"Suslow, A. et al. VAC-MAC consortium. Factors influencing vaccination decisions in patients with inflammatory rheumatic and musculoskeletal disease: a qualitative approach. BMC Rheumatol. 10, 11 https:\/\/doi.org\/10.1186\/s41927-025-00608-6 (2026).","journal-title":"BMC Rheumatol."},{"key":"1427_CR92","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/vaccines13121229","volume":"13","author":"IA Bellofatto","year":"2025","unstructured":"Bellofatto, I. A. et al. Coverage and drivers of vaccinations in patients with autoimmune rheumatic diseases: an Italian multicentric study. Vaccines 13, 1229 https:\/\/doi.org\/10.3390\/vaccines13121229 (2025).","journal-title":"Vaccines"},{"key":"1427_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.90012","volume":"8","author":"J Carrico","year":"2026","unstructured":"Carrico, J. et al. Herpes zoster vaccine uptake among United States adults with rheumatic disease: a mixed-methods analysis. ACR Open Rheumatol. 8, e90012 https:\/\/doi.org\/10.1002\/acr2.90012 (2026).","journal-title":"ACR Open Rheumatol."},{"key":"1427_CR94","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3899\/jrheum.2025-0934","volume":"53","author":"NA Davis","year":"2026","unstructured":"Davis, N. A. et al. Investigating factors associated with respiratory syncytial virus vaccination and breakthrough infection among patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 53, 199\u2013205 https:\/\/doi.org\/10.3899\/jrheum.2025-0934 (2026).","journal-title":"J. Rheumatol."},{"key":"1427_CR95","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2535755","volume":"21","author":"EM La","year":"2025","unstructured":"La, E. M., McGuiness, C. B., Singer, D., Yasuda, M. & Chen, C. C. RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023\u20132025 vaccination seasons. Hum. Vaccin. Immunother. 21, 2535755 https:\/\/doi.org\/10.1080\/21645515.2025.2535755 (2025).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1427_CR96","doi-asserted-by":"publisher","first-page":"e002562","DOI":"10.1136\/rmdopen-2022-002562","volume":"8","author":"S Neusser","year":"2022","unstructured":"Neusser, S. et al. Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review. RMD Open 8, e002562 https:\/\/doi.org\/10.1136\/rmdopen-2022-002562 (2022).","journal-title":"RMD Open"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01427-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01427-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01427-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:05:20Z","timestamp":1792670720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-026-01427-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1038\/s41584-026-01427-w","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"11 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. has received research grants from GSK, Pfizer and Roche.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}